Equities research analysts expect Allergan PLC. (NYSE:AGN) to announce $4.05 billion in sales for the current fiscal quarter, according to Zacks. Sixteen analysts have issued estimates for Allergan PLC.’s earnings, with the highest sales estimate coming in at $4.17 billion and the lowest estimate coming in at $3.95 billion. Allergan PLC. posted sales of $3.62 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 11.9%. The company is scheduled to report its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Allergan PLC. will report full year sales of $4.05 billion for the current financial year, with estimates ranging from $15.81 billion to $16.02 billion. For the next fiscal year, analysts expect that the company will report sales of $16.84 billion per share, with estimates ranging from $16.16 billion to $17.57 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Allergan PLC..

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company earned $3.35 EPS.

Several research analysts have recently issued reports on AGN shares. Cantor Fitzgerald reiterated a “hold” rating and set a $231.00 price target on shares of Allergan PLC. in a report on Friday, September 22nd. UBS AG reiterated an “outperform” rating and set a $275.00 price target on shares of Allergan PLC. in a report on Wednesday, August 9th. BidaskClub downgraded shares of Allergan PLC. from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Mizuho reiterated a “buy” rating and set a $267.00 price target on shares of Allergan PLC. in a report on Monday. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $280.00 price target (up from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $271.84.

COPYRIGHT VIOLATION NOTICE: “$4.05 Billion in Sales Expected for Allergan PLC. (AGN) This Quarter” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/28/4-05-billion-in-sales-expected-for-allergan-plc-agn-this-quarter.html.

Hedge funds have recently added to or reduced their stakes in the company. Honeywell International Inc. boosted its position in shares of Allergan PLC. by 13.6% during the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock worth $40,871,000 after purchasing an additional 20,100 shares in the last quarter. Israel Discount Bank of New York bought a new position in shares of Allergan PLC. during the 1st quarter worth about $988,000. Palladium Partners LLC boosted its position in shares of Allergan PLC. by 1.7% during the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock worth $7,575,000 after purchasing an additional 523 shares in the last quarter. Trust Co. of Vermont boosted its position in shares of Allergan PLC. by 62.8% during the 1st quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock worth $687,000 after purchasing an additional 1,109 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of Allergan PLC. during the 2nd quarter worth about $41,345,000. 82.02% of the stock is currently owned by institutional investors.

Allergan PLC. (NYSE AGN) opened at 208.30 on Thursday. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The company has a market capitalization of $69.64 billion, a price-to-earnings ratio of 6.35 and a beta of 1.18. The firm has a 50-day moving average price of $229.79 and a 200-day moving average price of $236.07.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.34%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

Allergan PLC. declared that its board has initiated a share buyback program on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get a free copy of the Zacks research report on Allergan PLC. (AGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.